Historical Treatment of Eosinophilia in India (1960s-1970s)
In India 50-60 years ago, the primary treatment for eosinophilia was diethylcarbamazine (DEC/Hetrazan), which was the standard modern therapy, alongside traditional Ayurvedic preparations that were also commonly used. 1
Historical Context and Treatment Approaches
Modern Medical Treatment
During the 1960s-1970s period in India, Hetrazan (diethylcarbamazine) was the established modern control drug used for treating eosinophilia, particularly tropical eosinophilia which was highly prevalent in the Indian subcontinent 1. This medication specifically targeted the parasitic causes of eosinophilia that were endemic to the region, including:
- Filariasis (a major cause of tropical pulmonary eosinophilia)
- Intestinal helminthic infections
- Other parasitic infestations common in tropical regions
Traditional Ayurvedic Treatment
Parallel to modern medicine, Ayurvedic compounds were widely used, consisting of:
- Swasakutara (a traditional respiratory formulation)
- Curcuma longa (Haridra/Turmeric)
- Withania somnifera (Ashwagandha)
Clinical trials from that era demonstrated that these Ayurvedic preparations provided complete relief of most clinical signs and symptoms and significantly reduced ESR (erythrocyte sedimentation rate), though they did not affect circulating eosinophil levels 1.
Clinical Approach in That Era
The treatment paradigm focused primarily on:
- Parasitic causes: Given India's tropical climate and sanitation challenges, most eosinophilia cases were presumed parasitic until proven otherwise
- Symptomatic relief: Both modern and traditional medicines aimed at controlling respiratory symptoms, fever, and systemic manifestations
- Empirical treatment: Often initiated without extensive diagnostic workup due to limited laboratory facilities
Important Historical Note
This historical treatment approach differs dramatically from current evidence-based management, which emphasizes identifying the underlying cause (secondary vs. primary eosinophilia) before initiating targeted therapy. The modern approach includes molecular testing, cytogenetics, and targeted therapies like tyrosine kinase inhibitors for specific genetic subtypes—none of which were available 50-60 years ago.